Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Inclusion Criteria:

Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:

Primary refractory disease (no complete response [CR] after ≥ 2 induction therapies)
Relapsed disease not in CR after ≥ 1 course of standard reinduction therapy
Secondary AML from myelodysplastic syndromes
Disease relapsed ≥ 2 months after transplant and no option of donor lymphocyte infusions (e.g., recipients of autologous or umbilical cord blood transplants)
Chronic myelogenous leukemia with myeloid blast crisis not in second chronic phase after at least one cycle of standard chemotherapy and imatinib
Over 60 years of age with relapse within 6 months after completion of last chemotherapy
Over 60 years of age with blast count < 30% within 10 days before study entry
Related HLA-haploidentical natural killer cell donor available
No severe organ damage (by clinical or laboratory assessment)
Performance status 50-100%
No evidence of active infection on chest X-ray
No active fungal infection

Exclusion Criteria:

Active central nervous system (CNS) leukemia
Pleural effusions large enough to be detectable by chest x-ray
Pregnant or nursing (positive pregnancy test)
Fertile patients must use effective contraception
Less than 60 days since prior transplant
Less than 3 days since prior prednisone
Less than 3 days since other prior immunosuppressive medication